Peptides for Mitochondrial Health: SS-31, MOTS-c, Humanin & More

Mitochondrial dysfunction sits at the center of aging biology. As mitochondria deteriorate — producing less ATP, leaking more reactive oxygen species (ROS), and accumulating DNA mutations — the downstream consequences cascade across every organ system. Cardiovascular disease, neurodegeneration, metabolic syndrome, sarcopenia, and the general decline of tissue function with age all have mitochondrial components.

This has made mitochondria a primary target for longevity and performance interventions. Several peptides directly target mitochondrial function, either by localizing to mitochondrial membranes, by being encoded within the mitochondrial genome itself, or by influencing mitochondrial biogenesis pathways. This guide examines the most significant mitochondrial peptides and what the evidence shows.

Mitochondrial Biology: The Essential Context

The Electron Transport Chain

Mitochondria generate ATP through oxidative phosphorylation (OXPHOS) in the electron transport chain (ETC). Four protein complexes (I through IV) embedded in the inner mitochondrial membrane pass electrons from NADH and FADH2 to oxygen, pumping protons across the membrane to create an electrochemical gradient. ATP synthase (Complex V) uses this gradient to phosphorylate ADP to ATP.

This process is remarkably efficient but inherently leaky. Approximately 0.1 to 2% of electrons escape the chain (primarily at Complexes I and III) and react with oxygen to form superoxide, the primary mitochondrial ROS. This electron leak is the fundamental source of oxidative stress in cells and increases with age and disease.

Mitochondrial Membranes

The inner mitochondrial membrane (IMM) is critical to mitochondrial function. Its lipid composition, particularly the content of cardiolipin (a phospholipid unique to mitochondria), determines ETC efficiency. Cardiolipin anchors ETC complexes into supercomplexes (respirasomes) that facilitate efficient electron transfer and minimize ROS production. When cardiolipin is oxidized or depleted, supercomplexes disassemble, electron leak increases, and ATP production falls.

The outer mitochondrial membrane (OMM) regulates molecular transport and plays a role in apoptosis signaling (cytochrome c release through mitochondrial permeability transition pore opening).

Mitochondrial DNA

Mitochondria contain their own circular DNA genome (mtDNA, approximately 16,500 base pairs in humans) encoding 13 ETC subunits, 2 rRNAs, and 22 tRNAs. mtDNA is particularly vulnerable to damage because it lacks histones, has limited repair mechanisms, and sits adjacent to the ETC — the primary source of intracellular ROS. mtDNA mutations accumulate with age and contribute to age-related mitochondrial dysfunction.

Critically, the mitochondrial genome also encodes small open reading frames that produce mitochondrial-derived peptides (MDPs). This relatively recent discovery has opened an entirely new chapter in mitochondrial biology.

SS-31 (Elamipretide): Targeting the Inner Membrane

What Is SS-31

SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2), also known as elamipretide or Bendavia, is a synthetic tetrapeptide designed to target the inner mitochondrial membrane. It was developed by Hazel Szeto and Peter Bhatt at Weill Cornell Medical College. The alternating aromatic-cationic structure allows it to concentrate in the inner mitochondrial membrane at >1000-fold its extracellular concentration.

Mechanism of Action

Cardiolipin interaction. SS-31's primary mechanism is interaction with cardiolipin on the inner mitochondrial membrane. By stabilizing cardiolipin-protein interactions, SS-31 maintains ETC supercomplex organization, improving electron transfer efficiency and reducing electron leak.

ROS reduction. By stabilizing electron flow through the ETC, SS-31 reduces superoxide production at its source rather than scavenging ROS after they are produced. This is a fundamentally different approach from conventional antioxidants (vitamin C, vitamin E, N-acetylcysteine), which attempt to neutralize ROS in the cytoplasm after they have already been generated and have already caused damage.

Cytochrome c optimization. SS-31 interacts with cytochrome c at the inner membrane surface, optimizing its electron carrier function and reducing its peroxidase activity (which contributes to cardiolipin oxidation in a destructive feedback loop).

Mitochondrial permeability transition pore (mPTP) inhibition. SS-31 reduces mPTP opening, which prevents pathological release of cytochrome c and activation of apoptotic cascades.

ATP production. By restoring ETC efficiency, SS-31 increases ATP production in dysfunctional mitochondria. Notably, it does not increase ATP production in healthy mitochondria operating near maximum efficiency — it restores function toward normal rather than pushing beyond normal.

Preclinical Evidence

SS-31 has one of the most extensive preclinical datasets of any peptide in development:

Heart failure. In multiple models of heart failure (pressure overload, ischemia-reperfusion, doxorubicin cardiotoxicity), SS-31 improved cardiac function, reduced infarct size, and improved mitochondrial respiration. The heart is the most mitochondria-dense organ (mitochondria constitute approximately 30% of cardiomyocyte volume), making it particularly responsive to mitochondrial-targeted therapies.

Skeletal muscle aging. In aged mice, SS-31 treatment reversed age-related declines in mitochondrial function, improved exercise capacity, and reversed age-related changes in the skeletal muscle proteome. Remarkably, some of these changes occurred within days of treatment, suggesting that mitochondrial dysfunction in aged muscle is at least partially reversible.

Kidney disease. SS-31 improved mitochondrial function and reduced proteinuria in models of diabetic nephropathy, ischemia-reperfusion injury, and unilateral ureteral obstruction.

Neurodegeneration. In models of Alzheimer's disease, Parkinson's disease, and ALS, SS-31 reduced mitochondrial dysfunction, oxidative stress, and neuronal death.

Ischemia-reperfusion injury. Across multiple organ systems (heart, kidney, brain), SS-31 reduced ischemia-reperfusion injury by protecting mitochondria during the reperfusion phase when ROS production surges.

Clinical Trials

SS-31/elamipretide has advanced into multiple human clinical trials:

Barth syndrome. The TAZPOWER trial in Barth syndrome (a genetic cardiomyopathy caused by defective cardiolipin remodeling) showed improvements in the 6-minute walk test and patient-reported outcomes. Elamipretide received FDA Fast Track designation for Barth syndrome. However, subsequent trials had mixed results, and the regulatory path has been complex.

Heart failure with reduced ejection fraction (HFrEF). The EMBRACE-STEMI trial evaluated elamipretide in ST-elevation myocardial infarction. Results were mixed — the primary endpoint (infarct size reduction by cardiac MRI) was not met, but secondary endpoints showed trends toward benefit.

Primary mitochondrial myopathy. Trials in patients with genetically confirmed mitochondrial disease have shown improvements in exercise tolerance and patient-reported outcomes.

Age-related macular degeneration (AMD). The ReCLAIM trial evaluated subcutaneous elamipretide for dry AMD. Results showed improvement in some visual function measures, suggesting that mitochondrial dysfunction contributes to retinal degeneration and that targeting it may be beneficial.

Evidence quality assessment: The most clinically advanced mitochondrial peptide. Multiple Phase II/III trials across multiple indications. The evidence supports mitochondrial targeting as a viable therapeutic strategy, though individual trial results have been mixed. The mechanism is well-characterized and biologically compelling.

MOTS-c: The Mitochondrial-Derived Exercise Mimetic

What Is MOTS-c

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the 12S rRNA gene of the mitochondrial genome. It was discovered in 2015 by Changhan David Lee's laboratory at USC. MOTS-c was one of the first mitochondrial-derived peptides (MDPs) identified and has generated intense research interest as a potential exercise mimetic and metabolic regulator.

Mechanism of Action

AMPK activation. MOTS-c activates AMP-activated protein kinase (AMPK), the master energy sensor of the cell. AMPK activation shifts cellular metabolism toward catabolic pathways: increased fatty acid oxidation, enhanced glucose uptake, stimulated mitochondrial biogenesis, and inhibited anabolic processes like lipogenesis and protein synthesis (when energy is limiting).

Methionine-folate cycle regulation. MOTS-c inhibits the methionine-folate cycle by blocking the enzyme MTHFD2, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator. This is the primary upstream mechanism through which MOTS-c activates AMPK.

Nuclear translocation. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it regulates gene expression related to antioxidant defense and metabolic adaptation. This is significant because it means a mitochondrial-encoded peptide directly regulates nuclear gene expression — a form of retrograde mito-nuclear signaling.

Glucose metabolism. MOTS-c enhances glucose uptake and utilization independently of insulin, potentially through AMPK-mediated GLUT4 translocation. This has implications for insulin resistance and metabolic syndrome.

Preclinical Evidence

Obesity prevention. In mice fed a high-fat diet, MOTS-c administration prevented obesity, improved insulin sensitivity, and reduced fat mass. The metabolic improvements were associated with increased skeletal muscle glucose uptake and fatty acid oxidation.

Exercise capacity. MOTS-c improved treadmill running capacity in young and old mice. Critically, the effect was more pronounced in aged mice, suggesting that MOTS-c partially reverses age-related declines in exercise capacity.

Aging. Endogenous MOTS-c levels decline with age in both mice and humans. In aged mice, MOTS-c administration improved physical function, suggesting that the age-related decline in MOTS-c contributes to functional decline.

Inflammation. MOTS-c modulated immune cell function and reduced inflammation in models of autoimmune disease, suggesting immunomodulatory properties beyond metabolic effects.

Bone health. MOTS-c has shown positive effects on bone metabolism, promoting osteoblast differentiation and reducing osteoclast activity in preclinical models.

Human Data

Endogenous levels. Studies in human populations have shown that circulating MOTS-c levels are higher in physically active individuals and decline with age. Certain mtDNA variants (particularly the m.1382A>C polymorphism, enriched in Japanese centenarians) are associated with higher MOTS-c levels, suggesting a genetic link between MOTS-c and longevity.

Exercise response. MOTS-c levels increase in response to acute exercise in humans, consistent with its role as an exercise-responsive mitochondrial signal.

Clinical trials. As of 2026, early-phase clinical trials evaluating exogenous MOTS-c administration in humans are underway but results have not been published in peer-reviewed literature. The primary endpoints include metabolic parameters (insulin sensitivity, glucose disposal) and exercise capacity.

Evidence quality assessment: Strong preclinical data with a clear, well-characterized mechanism. The exercise mimetic properties are compelling. Human correlative data supports the biological relevance. Clinical trial data in humans is pending. The endogenous origin (mitochondrial-encoded) provides biological plausibility that distinguishes MOTS-c from entirely synthetic compounds.

Humanin: The Mitochondrial Survival Signal

What Is Humanin

Humanin is a 24-amino acid peptide encoded within the 16S rRNA gene of the mitochondrial genome. Discovered in 2001 by Nishimoto and colleagues in a cDNA library from the surviving brain tissue of an Alzheimer's disease patient, Humanin was the first mitochondrial-derived peptide identified. Its name reflects the context of its discovery — a factor that appeared to protect human neurons from death.

Mechanism of Action

Anti-apoptotic effects. Humanin binds to and inhibits Bax, a pro-apoptotic protein that triggers mitochondrial outer membrane permeabilization. By preventing Bax insertion into the outer mitochondrial membrane, Humanin blocks cytochrome c release and downstream caspase activation. This is a direct, mitochondria-level anti-apoptotic mechanism.

IGFBP-3 interaction. Humanin binds to insulin-like growth factor-binding protein 3 (IGFBP-3), blocking IGFBP-3's pro-apoptotic effects. The Humanin-IGFBP-3 interaction links mitochondrial signaling to the IGF axis.

STAT3 signaling. Humanin activates the STAT3 signaling pathway through binding to the CNTFR/WSX-1/gp130 tripartite receptor complex. STAT3 activation promotes cell survival, reduces oxidative stress, and has anti-inflammatory effects.

FPRL1/FPRL2 receptors. Humanin binds to formyl peptide receptor-like proteins, modulating inflammatory and chemotactic responses.

Metabolic effects. Humanin improves insulin sensitivity and glucose homeostasis, effects that parallel MOTS-c but appear to operate through different signaling pathways (STAT3 for Humanin versus AMPK for MOTS-c).

Preclinical Evidence

Alzheimer's disease. Humanin and its more potent analogs (HNG, S14G-Humanin) have shown neuroprotective effects in multiple Alzheimer's models, reducing amyloid-beta toxicity, tau phosphorylation, and cognitive decline. This is consistent with Humanin's discovery context and anti-apoptotic mechanism.

Cardiovascular protection. Humanin reduced myocardial infarct size in ischemia-reperfusion models, improved cardiac function in models of heart failure, and reduced atherosclerotic plaque formation in ApoE-knockout mice.

Diabetes and metabolic syndrome. Humanin improved insulin sensitivity, reduced plasma glucose, and improved lipid profiles in rodent models of diabetes and metabolic syndrome.

Aging. Circulating Humanin levels decline with age in humans (approximately 40% decline between ages 20 and 80). In animal studies, Humanin administration improved healthspan markers in aged animals.

Human Data

Endogenous levels and aging. Serum Humanin levels decline progressively with age in large epidemiological cohorts. Lower Humanin levels are associated with higher rates of Alzheimer's disease, cardiovascular disease, and metabolic syndrome.

Genetic associations. The children of centenarians (who are themselves long-lived) have higher circulating Humanin levels than age-matched controls without centenarian parents, suggesting a heritable component to Humanin production that may influence longevity.

Clinical significance. Humanin levels are being investigated as a biomarker for mitochondrial health and biological age. However, no clinical trials of exogenous Humanin administration have been published as of 2026.

Evidence quality assessment: Strong biological discovery story. Well-characterized mechanism with multiple validated signaling pathways. Compelling epidemiological associations between endogenous levels and age-related disease. No exogenous administration trials in humans. The analogs (HNG, S14G-Humanin) are more potent than native Humanin and may be more suitable for therapeutic development.

Epitalon and Mitochondrial Effects

The Telomere-Mitochondria Connection

Epitalon (Ala-Glu-Asp-Gly) is primarily known as a telomerase activator, but its effects on mitochondrial function deserve discussion in this context.

Telomere shortening and mitochondrial dysfunction are interconnected through the p53-PGC-1alpha axis. As telomeres shorten critically, p53 activation suppresses PGC-1alpha (the master regulator of mitochondrial biogenesis), leading to reduced mitochondrial mass, impaired oxidative phosphorylation, and metabolic decline. This telomere-mitochondrial axis was characterized by DePinho and colleagues and represents a key mechanistic link between replicative aging and metabolic aging.

Epitalon's Effects on Mitochondria

Telomerase activation and downstream mitochondrial effects. By maintaining telomere length through telomerase activation, Epitalon may indirectly preserve mitochondrial function by preventing p53-mediated suppression of PGC-1alpha. This would maintain mitochondrial biogenesis and turnover (mitophagy) in aging cells.

Pineal gland function. Epitalon restores melatonin production in the pineal gland (which declines with age). Melatonin is itself a potent mitochondrial antioxidant that concentrates in mitochondria and scavenges ROS at the inner membrane. Through this pathway, Epitalon's melatonin-restoring effects provide indirect mitochondrial protection.

Gene expression. Studies in aging rat tissues have shown that Epitalon influences the expression of genes related to oxidative phosphorylation and mitochondrial function, though the specific pathways are not as well characterized as for SS-31 or the MDPs.

Evidence quality assessment for mitochondrial effects: The telomere-mitochondria axis is well-established in basic science. Epitalon's effects on mitochondria are primarily indirect (via telomerase and melatonin) rather than through direct mitochondrial targeting. The clinical evidence for Epitalon itself is limited to small studies conducted primarily by the Khavinson group in Russia. The mechanistic rationale is sound, but direct evidence for mitochondrial improvement from Epitalon is thin.

The NAD+ Connection

Why NAD+ Matters for Mitochondria

Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme for mitochondrial function. It serves as the primary electron carrier in the ETC (NADH donates electrons to Complex I) and is a required cofactor for sirtuins (SIRT1, SIRT3) that regulate mitochondrial biogenesis, fatty acid oxidation, and antioxidant defense.

NAD+ levels decline with age by approximately 50% between ages 30 and 70 in human tissues. This decline impairs mitochondrial function, reduces sirtuin activity, and contributes to the metabolic deterioration of aging.

Peptide-NAD+ Interactions

MOTS-c and the methionine-folate cycle. MOTS-c's inhibition of the methionine-folate cycle affects one-carbon metabolism, which intersects with NAD+ synthesis pathways. The relationship is complex, but MOTS-c's metabolic effects include alterations in NAD+/NADH ratios.

5-Amino-1MQ. While not a peptide (it is a small molecule), 5-Amino-1MQ is often discussed alongside mitochondrial peptides because it inhibits NNMT (nicotinamide N-methyltransferase), the enzyme that degrades nicotinamide (a NAD+ precursor) into methylnicotinamide. By blocking NNMT, 5-Amino-1MQ increases the availability of nicotinamide for NAD+ synthesis, theoretically boosting cellular NAD+ levels. This connects it mechanistically to mitochondrial function through the NAD+-sirtuin axis.

Humanin and sirtuin activation. Humanin's metabolic effects may partially depend on sirtuin activation, though the direct evidence for this pathway is still emerging.

Comparing Mitochondrial Peptides

Direct vs. Indirect Mitochondrial Targeting

The peptides in this guide operate at different levels of the mitochondrial hierarchy:

Direct inner membrane targeting: SS-31 is the only compound that physically localizes to the inner mitochondrial membrane and directly modulates ETC function. This makes it the most mechanistically direct mitochondrial therapy.

Mitochondrial-encoded retrograde signals: MOTS-c and Humanin are produced by mitochondria and communicate mitochondrial status to the rest of the cell (and to other cells through endocrine signaling). They represent the mitochondria's own adaptive response to stress.

Indirect mitochondrial support: Epitalon affects mitochondria through upstream pathways (telomerase, melatonin). These effects are real but less direct and less specific to mitochondria.

Evidence Maturity

Peptide	Clinical Trials	Mechanism Clarity	Aging Data	FDA Status
SS-31	Phase II/III	Very high	Preclinical	Fast Track (Barth)
MOTS-c	Early phase	High	Pre + human correlative	None
Humanin	None	High	Pre + human correlative	None
Epitalon	Very limited	Moderate (indirect)	Pre + limited human	None

Practical Considerations

Who Might Benefit from Mitochondrial Peptides

The individuals most likely to benefit from mitochondrial-targeted therapies are those with demonstrable mitochondrial dysfunction:

Aging individuals (50+). Mitochondrial function declines measurably after age 50. The decline in endogenous MOTS-c and Humanin levels parallels the decline in mitochondrial function.

Individuals with metabolic dysfunction. Insulin resistance, type 2 diabetes, and metabolic syndrome are all associated with impaired mitochondrial oxidative phosphorylation. MOTS-c's insulin-sensitizing effects are mechanistically targeted at this population.

Athletes and individuals with high metabolic demands. Mitochondrial efficiency directly determines aerobic capacity. SS-31's ability to optimize ETC function is relevant for endurance performance, though no human performance trials have been published.

Individuals with genetic mitochondrial disease. This is the population where SS-31/elamipretide has the most advanced clinical data (Barth syndrome, primary mitochondrial myopathy).

Current Limitations

No home mitochondrial function test. Unlike IGF-1 for GH peptides or fasting glucose for metabolic peptides, there is no simple blood test that tells you whether your mitochondria are functioning well or poorly. Organic acid tests (measuring mitochondrial metabolites in urine) and lactate/pyruvate ratios provide indirect assessment, but they are imprecise.

Dosing is not established. Except for SS-31 in clinical trial settings, optimal doses for MOTS-c, Humanin, and Epitalon in humans are not established. Research-grade use relies on extrapolation from preclinical studies and empirical observation.

Long-term safety data is absent. Chronic supplementation with mitochondrial peptides has not been studied in humans. While the endogenous origin of MOTS-c and Humanin provides some reassurance (you are supplementing molecules your body already makes), exogenous administration at supraphysiological levels could have unintended effects.

The longevity paradox. Some of the most robust longevity interventions in model organisms (caloric restriction, rapamycin, reduced IGF-1 signaling) work partly by activating mild mitochondrial stress responses (mitohormesis). There is a theoretical concern that making mitochondria "too efficient" by eliminating all ROS could blunt these adaptive stress responses. The relationship between mitochondrial function, ROS signaling, and longevity is more nuanced than "less ROS is always better."

The Future of Mitochondrial Peptide Therapy

The field of mitochondrial peptides is moving rapidly. Key developments to watch include:

Clinical trial results for MOTS-c. The first human dosing studies will establish whether the remarkable preclinical metabolic effects translate to humans.

Elamipretide regulatory decisions. Ongoing FDA review for multiple indications will determine whether the first mitochondrial-targeted peptide reaches the market.

New MDP discovery. Additional mitochondrial-derived peptides beyond MOTS-c and Humanin are being identified. SHLP1-6 (small Humanin-like peptides) encoded within the 16S rRNA gene represent the next wave of MDPs under investigation.

Mitochondrial transplantation. Emerging approaches involving direct mitochondrial transfer to damaged cells could complement peptide therapies.

Biomarker development. Better clinical biomarkers for mitochondrial function will enable more precise selection of patients who would benefit from these therapies and better monitoring of treatment responses.

Mitochondrial peptides represent a convergence of aging biology, metabolic medicine, and peptide pharmacology. The biological rationale is strong, the preclinical data is compelling, and the clinical translation is underway. Whether these molecules will become standard tools in longevity and metabolic medicine depends on the results of ongoing and upcoming clinical trials.